Organon to Acquire Dermavant Sciences Ltd. with Focus on Innovative Dermatologic Therapy VTAMA® (tapinarof) Cream, 1%
Acquiring Company
Organon
Acquired Company
Dermavant
Description
Organon, a global healthcare company focused on improving women's health, has announced the acquisition of Dermavant Sciences Ltd. This strategic move is aimed at expanding Organon's healthcare solutions by adding Dermavant's innovative dermatologic therapy VTAMA® (tapinarof) Cream, 1% for the treatment of psoriasis and atopic dermatitis.
Quick answer
Organon is acquiring Dermavant, announced September 18, 2024. Organon is based in Jersey City, New Jersey, United States.
- How much did Organon pay for Dermavant?
- The deal value was not disclosed.
- What does Organon do?
- Organon is a global healthcare company formed through a spin-off from Merck, (NYSE: MRK) known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives.
- Where are Organon and Dermavant based?
- Organon is based in Jersey City, New Jersey, United States. Dermavant is based in Long Beach, California, United States.
- Who are the decision-makers at Organon?
- Fundz holds 2 contacts at Organon. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Medical and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Organon successfully acquires Dermavant Sciences Ltd. to expand dermatology portfolio (October 28, 2024)
- Breeze Holdings Acquisition Corp. to merge with YD Biopharma Limited to revolutionize cancer prevention diagnostics (September 25, 2024)
- Flat Medical strengthens market leadership with acquisition of InjeQ assets, including FDA-Designated Breakthrough Device IQ-Tip® (September 25, 2024)
- Organon acquires Dermavant Sciences to obtain the groundbreaking skin treatment VTAMA® (tapinarof) cream 1% (September 19, 2024)
- KARL STORZ completes acquisition of Asensus Surgical, Inc. to strengthen its position in robotic and digital surgical market (August 22, 2024)
- Trinity Biotech plc acquires EpiCapture Limited to expand into oncology diagnostics (October 25, 2024)
Who to call at Organon, and when
When Organon changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Organon raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Organon, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Organon. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Organon makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Dermavant?
Dermavant was acquired by Organon, based in Jersey City. The deal was reported on September 18, 2024. Organon is a global healthcare company formed through a spin-off from Merck, (NYSE: MRK) known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Organon is publicly traded (OGN) and operates in Biotechnology.
When did Organon acquire Dermavant?
Organon's acquisition of Dermavant was reported on September 18, 2024. Organon, a global healthcare company focused on improving women's health, has announced the acquisition of Dermavant Sciences Ltd. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Dermavant do?
Dermavant is a biopharmaceutical company that specializes in developing innovative therapies for dermatological conditions. The company focuses on addressing unmet needs in dermatology. It aims to improve patients' lives with its innovative solutions. It is privately held, operating in Biotechnology, and is based in Long Beach.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.